|Awarded On||November 19, 2015|
|Title||Early Detection of Ovarian Cancer with Tumor Associated Proteins and Autoantibodies|
|Award Mechanism||Individual Investigator Research Awards for Prevention and Early Detection|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Robert Bast|
Currently available surgery and chemotherapy can cure 90% of women with cancer confined to the ovary (stage I) and 70% with disease limited to the pelvis (stage II). When ovarian cancer has spread further (stage III, IV), cure rates plummet to 20% or less. Ovarian cancer is diagnosed in early stage in only 20-25% of cases. We found that annual measurement of CA125 followed by ultrasound and surgery, if indicated, can detect early stage (I, II) ovarian cancer in 9 of 12 cases (75%). Three operations are required to diagnose each cancer using a mathematical formula (algorithm) that determines whether CA125 is rising. As CA125 is expressed by only 80% of ovarian cancers, additional bio...